Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Abbott Laboratories (ABT)

Abbott adds Nita Ahuja, M.D. to board and expands it to thirteen directors

Neutral Impact 2 of 5 leadership Written later

On December 12, 2025, Abbott Laboratories named Nita Ahuja, M.D. to its Board of Directors. The same day, the board amended the by-laws to set the board at thirteen persons, up from twelve, effective December 12, 2025. The filing does not describe Dr. Ahuja's background, committee roles, or compensation.

Key points

  • Nita Ahuja, M.D. was named to the Board of Directors on December 12, 2025.
  • Article III, Section 2 of the by-laws was amended so the board consists of thirteen persons, up from twelve.
  • The amended and restated by-laws are filed as Exhibit 99.1, effective December 12, 2025.

The filing

CompanyAbbott Laboratories (ABT)
Form8-K, current report
Filed with the SECDec 12, 2025, 4:10 PM ET
Accession number0001104659-25-120657

Items reported: 5.02 Director / Officer Change5.03 Bylaw / Charter Amendment

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 2:16 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on December 12, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.